Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 12, 2016, Pages 1450-1454

  Elfert, Asem ^a   Abo Ali, Lobna ^a   Soliman, Samah ^a   Ibrahim, Shimaa ^a   Abd Elsalam, Sherief ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

encephalopathy; norfloxacin; rifaximin; secondary prevention; spontaneous bacterial peritonitis

Indexed keywords

NORFLOXACIN; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CAUSE OF DEATH; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SEPSIS; BACTERIAL INFECTIONS; COMPARATIVE STUDY; COMPLICATION; EGYPT; MORTALITY; PERITONITIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ASCITES; BACTERIAL INFECTIONS; CAUSE OF DEATH; EGYPT; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORTALITY; NORFLOXACIN; PERITONITIS; RIFAMYCINS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84981543077     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000724     Document Type: Article

References (13)

1. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61:297-310
2. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818-824
3. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56 (Suppl 1):S1-S12
4. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26:17-25
5. Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46:709-715
6. Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (Pt 1):716-724
7. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120:726-748
8. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011; 17:1237-1248
9. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol 2012; 18:1700-1702
10. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with alcohol-related decompensated cirrhosis: a case control study. J Gastroenterol Hepatol 2013; 28:450-455
11. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59 (Suppl 2):54-57
12. Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532-536
13. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081